PubMed Health⌕ Search

PubMed · 11109396

[Should people with epilepsy exercise?].

Abstract

Many people with epilepsy, especially those with uncontrolled seizures, live a sedentary life and have low physical fitness. Regular physical exercise may have a moderate seizure preventive effect in 30-40% of the patient population, while in about 10%, strenuous exercise may provoke seizures. Among those prone to exercise-induced seizures there is a preponderance of patients with very poor physical fitness and symptomatic epilepsy. The underlying mechanisms of interaction between epilepsy and physical exercise are mainly unknown. As a general rule, people with epilepsy should be stimulated to participate in recreational and athletic activities. However, as this patient group is highly heterogeneous, counselling on this topic should be individualised and take into account both seizure type and frequency. A distinction may be drawn between three categories: activities with no restrictions, activities with some restrictions, and activities that are not advisable.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K O Nakken. 2000-10-20. [Should people with epilepsy exercise?].. https://pubmed.ncbi.nlm.nih.gov/11109396/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗